Asia-Pacific Blood Glucose Monitoring Devices Market Outlook, 2028

In Asia-Pacific, the growing spread of diabetes and the rise in demand for consistent glucose monitoring equipment are the key market drivers enhancing the market expansion. Glucose monitoring devices are used to detect the sugar level in our blood and are of several kinds, including a glucose metre, testing strips, and lancets. The use of these devices consumes less time than glucose testing by customary methods in laboratories. These devices can be controlled easily as they are portable and convenient to carry. They offer the facility of monitoring glucose levels in our blood as it tests quantitatively. The increasing prevalence of diabetes cases is due to an unhealthy lifestyle, and food habits resulting in considerable differences in health are expected to expand the market during the forecast period. According to NCBI, More than 60% of the people with diabetes live in Asia, with almost one-half in China and India combined. The Western Pacific, the world's most populous region, has more than 138.2 million people with diabetes, and the number may rise to 201.8 million by 2035. The aging population in many countries across Asia Pacific is on the rise. As age is a significant risk factor for diabetes, the increasing number of elderly individuals contributes to the overall demand for blood glucose monitoring devices. Rapid urbanization and changing lifestyles in the Asia Pacific region have led to an increased prevalence of sedentary behaviour and unhealthy dietary habits. These factors contribute to the rise in diabetes cases, fuelling the demand for blood glucose monitoring devices. The growing disposable income in several countries in the Asia Pacific region allows individuals to invest in healthcare, including the purchase of blood glucose monitoring devices. As economic conditions improve, more people can afford these devices, leading to increased market growth. Improving access to healthcare in rural areas is a key driver. Efforts to expand healthcare infrastructure and make blood glucose monitoring devices accessible to individuals in remote or underserved regions contribute to market growth. The adoption of mobile point-of-care testing for blood glucose monitoring is increasing. Mobile POCT devices are portable and can be used in various settings, including community health clinics and outreach programs.

According to the research report "Asia-Pacific Blood Glucose Monitor Market Outlook, 2028," published by Bonafide Research, the Asia Pacific Blood Glucose Monitor market is expected to add more than 2.40 Billion from 2023 to 2028. Blood glucose monitoring devices are increasingly integrating with mobile health applications. This integration enables users to conveniently track and analyze their glucose levels using smartphones, receive personalized insights, and share data with healthcare providers for remote monitoring. The adoption of wearable glucose monitoring devices, including smartwatches and other wearables, is on the rise. These devices offer continuous monitoring in a non-intrusive manner, aligning with the increasing demand for convenient and discreet monitoring solutions. Manufacturers are placing a greater emphasis on user-friendly design features in blood glucose monitoring devices. Intuitive interfaces, easy-to-use functionalities, and ergonomic designs enhance the overall user experience, catering to users of varying ages and technological familiarity. The integration of data analytics and artificial intelligence into blood glucose monitoring devices is growing. These technologies enable more sophisticated data analysis, predictive modeling, and the delivery of personalized insights for individuals managing diabetes. Some companies are exploring subscription-based models for blood glucose monitoring. This approach involves offering not just the device but also a range of associated services, including data analytics, personalized coaching, and continuous software updates. Blood glucose monitoring devices are increasingly becoming part of a broader wearable health technology ecosystem. Integration with other health and fitness monitoring devices allows users to track multiple health metrics in one comprehensive system. The integration of artificial intelligence (AI) in diabetes management apps is growing. These apps analyze user data from blood glucose monitors, provide predictive insights, and offer personalized recommendations for better self-management. Advancements in voice recognition technology have led to the development of voice-activated blood glucose monitoring devices. This innovation aims to enhance accessibility for individuals with visual impairments and those who prefer hands-free interactions.

In terms of country the market is categorized into China, Japan, India, Australia and South Korea. China has a rapidly aging population, and diabetes is more prevalent among older individuals. As the population ages, there is a higher likelihood of diabetes diagnosis and management, leading to an increased need for blood glucose monitoring devices among the elderly. According to the World Health Organization (WHO), about 110 million people in China have diabetes. This is almost 10% of all adults in the country. China is undergoing rapid urbanization, which is also a risk factor for diabetes. Urban populations are more likely to have unhealthy lifestyles, such as a lack of physical activity and a diet high in processed foods and sugary drinks. Diabetes is a major economic burden in China. Furthermore, South Korea has witnessed a rise in the prevalence of diabetes, both Type 1 and Type 2. The increasing number of individuals diagnosed with diabetes creates a growing demand for blood glucose monitoring devices to manage and monitor the condition effectively. The aging population in South Korea is more susceptible to diabetes. As the proportion of elderly individuals increases, so does the need for blood glucose monitoring devices to cater to this demographics healthcare needs.

The market is segmented into various product categories, such as Self-monitoring Devices and Continuous Blood Glucose Monitoring Devices. Among them, Continuous Blood Glucose Monitoring Devices market is expected to witness the highest CAGR during the forecast period. Although CGM is an advanced method for people living with diabetes to check glucose readings in real time, SMBGs are the most preferred devices by patients in Asia-Pacific due to their economic affordability and lesser sophistication in usage when compared to CGM. Continuous Blood Glucose Monitoring devices provide real-time data on glucose levels, allowing individuals with diabetes and healthcare professionals to closely monitor fluctuations throughout the day. This continuous monitoring capability offers a more comprehensive and dynamic view compared to traditional self-monitoring devices. CGM devices often come with user-friendly interfaces and mobile app integrations, enabling individuals to actively engage in their diabetes management. The ability to track trends, set alerts, and receive immediate feedback enhances patient involvement in the management process. The continuous nature of CGM allows for a more personalized and dynamic approach to treatment plans. By providing actionable insights in real-time, individuals are better equipped to make timely adjustments to their medication, diet, and lifestyle, improving overall adherence to treatment recommendations. CGM devices often come equipped with wireless connectivity features, allowing seamless data transfer to smartphones or other digital platforms. This connectivity enhances user convenience and promotes the integration of glucose data into broader digital health ecosystems. CGM devices allow users to customize alerts based on their individual preferences and glycemic targets. Personalized alerts for high or low glucose levels contribute to a more individualized and responsive diabetes management approach.

Based on end user, Hospitals serve as central hubs for comprehensive diabetes care. They often have specialized diabetes clinics or endocrinology departments that provide centralized management for patients with diabetes. Blood glucose monitoring devices used in hospitals are part of an integrated approach to diabetes care. Hospitals are primary settings for acute care, where patients with severe diabetes-related complications may receive treatment. Continuous Blood Glucose Monitoring (CGM) devices, point-of-care testing, and other monitoring tools are crucial in these acute care settings for immediate and accurate glucose level assessment. Patients admitted to hospitals, whether for diabetes-related issues or other health concerns, require regular monitoring of their blood glucose levels. Hospitals use blood glucose monitoring devices to track and manage glucose levels in inpatient settings, ensuring timely intervention when needed. Hospitals often have sophisticated health information systems, including Electronic Health Records (EHRs). Blood glucose monitoring devices used in hospitals are integrated with these systems, allowing seamless documentation of patient data and facilitating communication among healthcare professionals. Patients undergoing surgeries or organ transplants, especially those with pre-existing diabetes, require close monitoring of their blood glucose levels during the post-operative period. Hospitals play a critical role in post-surgery and post-transplant care, utilizing blood glucose monitoring devices to manage glycemic control.



Companies Covered in this report:

F. Hoffmann-La Roche AG, Abbott Laboratories, Nipro Corporation, B. Braun Melsungen AG, Medtronic plc, DexCom, Inc, Bionime Corporation.

Considered in this report

• Geography: Asia Pacific
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report

• Asia Pacific Blood Glucose Monitoring Devices market Outlook with its value and forecast along with its segments
• Country-wise Blood Glucose Monitoring Devices market analysis
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

Country covered in the report:

• China
• Japan
• India
• Australia
• South Korea

By Product

• Self-monitoring Devices
• Continuous Blood Glucose Monitoring Devices

By End User

• Hospitals
• Home Care
• Diagnostic Centers

By Indication

• Diabetes
• Pregnancy
• Cardiovascular Disorders & Hypertension
• Cancer
• Respiratory Diseases
• Movement Disorders
• Hearing Disorders
• Wound Care
• Other Indications (sleep disorders, kidney disorders, neurovascular diseases, and HIV)

The approach of the report:

This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases. After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this; we have started making primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once we have primary data with us, we can start verifying the details obtained from secondary sources.

Intended audience

This report can be useful to industry consultants, manufacturers, suppliers, associations, and organisations related to the Blood Glucose Monitoring Devices industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.